A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder
Journal of Clinical Psychopharmacology - United States
doi 10.1097/jcp.0b013e31825d70d6
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2012
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)